230 related articles for article (PubMed ID: 34572038)
1. 26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy.
Rubio AJ; Bencomo-Alvarez AE; Young JE; Velazquez VV; Lara JJ; Gonzalez MA; Eiring AM
Cells; 2021 Sep; 10(9):. PubMed ID: 34572038
[TBL] [Abstract][Full Text] [Related]
2. Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.
Bencomo-Alvarez AE; Rubio AJ; Olivas IM; Gonzalez MA; Ellwood R; Fiol CR; Eide CA; Lara JJ; Barreto-Vargas C; Jave-Suarez LF; Nteliopoulos G; Reid AG; Milojkovic D; Druker BJ; Apperley J; Khorashad JS; Eiring AM
Oncogene; 2021 Apr; 40(15):2697-2710. PubMed ID: 33712704
[TBL] [Abstract][Full Text] [Related]
3. 19S Proteasome Subunits as Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML).
Lara JJ; Bencomo-Alvarez AE; Gonzalez MA; Olivas IM; Young JE; Lopez JL; Velazquez VV; Glovier S; Keivan M; Rubio AJ; Dang SK; Solecki JP; Allen JC; Tapia DN; Tychhon B; Astudillo GE; Jordan C; Chandrashekar DS; Eiring AM
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498916
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer.
Tychhon B; Allen JC; Gonzalez MA; Olivas IM; Solecki JP; Keivan M; Velazquez VV; McCall EB; Tapia DN; Rubio AJ; Jordan C; Elliott D; Eiring AM
Front Med (Lausanne); 2023; 10():1209425. PubMed ID: 37502358
[TBL] [Abstract][Full Text] [Related]
5. Depleting the 19S proteasome regulatory PSMD1 subunit as a cancer therapy strategy.
Adler J; Oren R; Shaul Y
Cancer Med; 2023 May; 12(9):10781-10790. PubMed ID: 36934426
[TBL] [Abstract][Full Text] [Related]
6. Proteasome 26S subunit, non-ATPase 1 (PSMD1) facilitated the progression of lung adenocarcinoma by the de-ubiquitination and stability of PTEN-induced kinase 1 (PINK1).
Liu L; Liu A; Dong J; Zuo Z; Liu X
Exp Cell Res; 2022 Apr; 413(2):113075. PubMed ID: 35192838
[TBL] [Abstract][Full Text] [Related]
7. Depletion of proteasome subunit PSMD1 induces cancer cell death via protein ubiquitination and DNA damage, irrespective of p53 status.
Kim MY; Park ER; Cho EH; Park SH; Han CJ; Kim SB; Gu MB; Shin HJ; Lee KH
Sci Rep; 2024 Apr; 14(1):7997. PubMed ID: 38580756
[TBL] [Abstract][Full Text] [Related]
8. PSMD3-ILF3 signaling cascade drives lung cancer cell proliferation and migration.
Zhang J; Ma Q; Yu Q; Xiao F; Zhang Z; Feng H; Liang C
Biol Direct; 2023 Jun; 18(1):33. PubMed ID: 37337223
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients.
Xuan DTM; Wu CC; Kao TJ; Ta HDK; Anuraga G; Andriani V; Athoillah M; Chiao CC; Wu YF; Lee KH; Wang CY; Chuang JY
Aging (Albany NY); 2021 Nov; 13(22):24882-24913. PubMed ID: 34839279
[TBL] [Abstract][Full Text] [Related]
10. NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1.
Craxton A; Butterworth M; Harper N; Fairall L; Schwabe J; Ciechanover A; Cohen GM
Cell Death Differ; 2012 Sep; 19(9):1424-34. PubMed ID: 22361683
[TBL] [Abstract][Full Text] [Related]
11. Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation.
Fararjeh AS; Chen LC; Ho YS; Cheng TC; Liu YR; Chang HL; Chang HW; Wu CH; Tu SH
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31013812
[TBL] [Abstract][Full Text] [Related]
12. Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation.
Okumura T; Ikeda K; Ujihira T; Okamoto K; Horie-Inoue K; Takeda S; Inoue S
J Biochem; 2018 Jan; 163(1):19-29. PubMed ID: 28992264
[TBL] [Abstract][Full Text] [Related]
13. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
15. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Johnson DE
Endocr Relat Cancer; 2015 Feb; 22(1):T1-17. PubMed ID: 24659480
[TBL] [Abstract][Full Text] [Related]
16. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
Schmidt M; Altdörfer V; Schnitte S; Fuchs AR; Kropp KN; Maurer S; Müller MR; Salih HR; Rittig SM; Grünebach F; Dörfel D
Neoplasia; 2019 Jul; 21(7):653-664. PubMed ID: 31132676
[TBL] [Abstract][Full Text] [Related]
17. SUMOylation of Psmd1 controls Adrm1 interaction with the proteasome.
Ryu H; Gygi SP; Azuma Y; Arnaoutov A; Dasso M
Cell Rep; 2014 Jun; 7(6):1842-8. PubMed ID: 24910440
[TBL] [Abstract][Full Text] [Related]
18. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
19. Proteasome deubiquitinases as novel targets for cancer therapy.
D'Arcy P; Linder S
Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
[TBL] [Abstract][Full Text] [Related]
20. ATG16 mediates the autophagic degradation of the 19S proteasomal subunits PSMD1 and PSMD2.
Xiong Q; Fischer S; Karow M; Müller R; Meßling S; Eichinger L
Eur J Cell Biol; 2018 Nov; 97(8):523-532. PubMed ID: 30269947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
